A team led by Massachusetts General Hospital (MGH) investigators has confirmed that the imaging agent Pittsburgh Compound B (PiB) binds to the protein in amyloid plaques that characterize Alzheimer's disease in the human brain. Their report in the March Archives of Neurology describes the first postmortem neuropathological study of a dementia patient who had previously participated in a PET imaging study using PiB.
"This report is an essential validation of the use of PET imaging with PiB to identify amyloid-beta deposits in the brain and as a marker of disease progression that could be used to track the benefit of new treatments," says John Growdon, MD, director of the MGH Memory Disorders Unit, the paper's senior author. "It also indicates that the interpretation of PiB PET scanning needs to be done in the context of a patient's clinical symptoms and other diagnostic studies."
Alzheimer's disease is characterized by plaques within the brain of amyloid-beta protein, which is toxic to brain cells. Previous studies have shown that PiB, invented by researchers at the University of Pittsburgh School of Medicine, binds to amyloid-beta in the brains of mice and can be detected by PET scan in the brains of human patients with a diagnosis of probable Alzheimer's disease. But since a definitive Alzheimer's diagnosis can be made only on autopsy, there had been no confirmation that PiB in human brains was detecting amyloid-beta deposits.
The Archives of Neurology report describes the case of an elderly man with symptoms that could indicate several neurological disorders. He was evaluated numerous times over a period of three years, including a standard PET scan that produced results suggesting Alzheimer's disease. His eventual diagnosis was dementia with Lewy bodies, a condition that can exist along with Alzheimer's. He also enrolled in a research study involving PiB imaging, and the results of his scan showed the imaging compound had been taken up throughout the cerebral cortex, the outer layer of the brain. Three months after participating in the imaging study, the patient died at the age of 76 following a head injury, and an autopsy was performed.
The autopsy confirmed the diagnosis of dementia with Lewy bodies and had several findings characteristic of Alzheimer's disease. While some plaques that typify Alzheimer's were seen, most amyloid-beta was found in the walls of blood vessels, a condition known as cerebral amyloid angiopathy.
"The distribution of amyloid seen at autopsy matched the overall distribution seen in the PiB imaging study; levels were higher in the cerebral cortex than in other areas of the brain," says Matthew Frosch, MD, PhD, of the MassGeneral Institute for Neurodegenerative Diseases (MGH-MIND), a study co-author. "Features of Alzheimer's pathology, amyloid plaques and neurofibrillary tangles, were observed, but not at a level that would support a separate diagnosis of Alzheimer's disease."
The researchers note that, while their results confirm that uptake of PiB indicates the presence of amyloid in the brain, a positive PiB PET scan cannot be equated with a definitive Alzheimer's diagnosis. "About 15 percent of control participants in previous PiB studies, people with no cognitive impairment, had some level of PiB uptake," says Brian Bacskai, PhD, of MGH-MIND, the paper's lead author. "Some participants who probably had Alzheimer's had low uptake, and uptake levels varied for those with a diagnosis of mild cognitive impairment. Once a safe and effective drug for removing amyloid from the brain or preventing its accumulation is developed, it will be important to see how closely PiB PET scans can track those effects."
Sue McGreevey | EurekAlert!
Real-time feedback helps save energy and water
08.02.2017 | Otto-Friedrich-Universität Bamberg
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
24.02.2017 | Life Sciences
24.02.2017 | Life Sciences
24.02.2017 | Trade Fair News